Surat: Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter ended December 31, 2025.
Consolidated Financial Highlights for Quarter ended December 31, 2025:
- Total revenue for Q3FY26 was at ₹5,145 million as compared to ₹3,866 million in Q3FY25; up 33% YoY.
- EBITDA (incl. other income) was at ₹1,296 million in Q3FY26 as compared to ₹1,208 million in Q3FY25, up 7% and this would translate into 25.20% EBITDA margin in this quarter.
- Profit After Tax was at ₹606 million in Q3FY26 as compared to ₹542 million in Q3FY25; up 12% YoY.
Speaking on the performance, Anand Desai, Managing Director, Anupam Rasayan commented, “I am pleased to share that for the nine months of FY26, we delivered consolidated revenue of ₹17,297 million with EBITDA of ₹4,024 million, reflecting strong year-on-year growth.
For Q3 FY26, revenue stood at ₹5,124 million with EBITDA of ₹1,296 million, demonstrating continued growth momentum.
A significant strategic development during the period has been the signing of a definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States.
This acquisition strengthens our global footprint, enhances our capabilities in advanced custom synthesis, and deepens our access to regulated markets and innovator customers in North America. It represents an important step in our journey toward becoming a global specialty chemical platform.
